Nefrojenik Sistemik Fibrozis: Gadolinyuma bağlı yeni bir klinik antite

Yıl 2011, Cilt: 18 Sayı: 3, 107 - 109, 30.09.2011

Mehmet Munduz Mert Köroğlu Ahmet Yeşildağ Önem Altıntaş

Öz

Gelişen teknolojinin en güzel örneklerinden biri olan MRG (Magnetik Rezonans Görüntüleme), tanı koymada mükemmel avantajlar sağlamaktadır. Bazı patolojik durumların tanısında MRG kontrast ajanlarına gereksinim duyulmaktadır. MRG kontrast ajanları son derece güvenilir olarak tanımlanmaktadır. Fakat son zamanlarda sıkça adından bahsedilen bir klinik antite olan Nefrojenik Sistemik Fibrozis (NSF), MR kontrast ajanlarını yeniden gözden geçirmek için uyarıcı olmuştur.
Anahtar kelimeler: MRG, kontrast madde, Nefrojenik Sistemik Fibrozis

Abstract

Nephrogenic Systemic Fibrosis: A new clinical entity associated with exposure to gadolinium

MRI(Magnetic Resonance Imaging), is one of the best examples of advancing technology, provides excellent benefits for diagnosis. We need to use MRI contrast agents for diagnosing of some pathological conditions. MRI contrast agents have been defined as extremely reliable. But recently, NSF(Nephrogenic systemic fibrosis) which is frequently mentioned as a clinical entity, has been stimulating to review MR contrast agents.

Key words: MRI, contrast agents, Nephrogenic Systemic Fibrosis

Anahtar Kelimeler

MRG, kontrast maddeler, Nefrojenik Sistemik Fibrozis

Kaynakça

• Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera- Velazquez S, Jimenez SA: Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature.Semin Arthritis Rheum 2006; 35: 238–249.
• Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23: 383-91.
• High WA, Eng M, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 710–712.
• Wael M. Shabana, Richard H. Cohan, James H. Ellis, Hero K. Hussain, Isaac R. Francis, Lyndon D. Su, Suresh K. Mukherji and Richard D. Swartz. Nephrogenic Systemic Fibrosis: A Report of 29 Cases. AJR 2008; 190: 736-741.
• Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007; ;22: 3174–3178.
• Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-8.
• Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic Fibrosing Dermopathy: A novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003; 114: 563–72.
• Sadowski EA, Bennett LK, Chan MR. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148–157.
• Collidge TA, Thomson OC, Mark PB. Gadolinium- enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007; 245: 168–175.
• Ortonne N, Lipsker D, Chantrel F, Boehm N, Grosshans E, Cribier B. Presence of CD45RO1 CD341 cells with collagen synthesis activity in nephrogenic fibrosing dermopathy; a new pathogenic hypothesis. Br J Dermatol 2004; 150: 1050-2.
• Greenen RWF, Krestin GF: Non-tissue specific extracellular MR contrast media. In: Contrast Media: Safety Issues and ESUR Guidelines, edited by Thomsen HS, Heidelberg,Springer, 2006, pp 107–113
• Joffe P, Thomsen HS, Meusel M: Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5: 491–502.
• Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-62.
• Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139:903-09.
• Jimenez SA, Arlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, et al. Dialysis-Associated Systemic Fibrosis (Nephrogenic Fibrosing Dermopathy). Arthritis Rheum 2004; 50: 2660–66.
• Levine JM, Taylor RA, Elman LB, Bird SJ, Lavi E, Stolzenberg ED, et al. Involvement of skeletal muscle in dialysis-associated fibrosis (Nephrogenic Fibrosing Dermopathy). Muscle & Nevre 2004; 30: 569–77.
• Chiu H, Wells G, Carag H, Canova E, Firpi RJ. Nephrogenic fibrosing dermopathy: a rare entity in patients awaiting liver transplantation. Liver Transpl 2004; 10: 465–66.
• Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003; 15: 785–90.
• Hauser C, Kaya G, Chizzolini C. Nephrogenic fibrosing dermopathy in a renal transplant recipient with tubulointerstitial nephritis and uveitis. Dermatology 2004; 209: 50–52.
• Lauchli S, Zortea-Caflisch C, Nestle FO, Burg G, Kempf W. Nephrogenic fibrosing dermopathytreated with extracorporeal photopheresis. Dermatology 2004; 208: 278–80.
• Jan F, Segal JM, Dyer J, LeBoit P, Siegfried E, Frieden IJ. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 2003; 143: 678–81.
• Perazella MA, Ishibe S, Perazella MA, Reilly RF. Nephrogenic fibrosing dermopathy: an unusual skin condition associated with kidney disease. Semin Dial 2003; 16: 276–80.